Citius Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing critical care drug products, has signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome (ARDS) from a subsidiary of Novellus, a preclinical-stage biotechnology company based in Cambridge, MA.   Novellus’s patented process uses its exclusive non-immunogenic synthetic messenger ribonucleic acid (mRNA) molecules to create induce...